Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma

International Journal of Cancer

Volumn 140, Issue 9, 2017, Pages 2092-2100

  Nicolas Parraga S ^a,b   Alemany, L ^a,b   de Sanjose S ^a,b,c   Bosch, F X ^a,b   Bravo, I G ^a,d  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d CNRS   (France)

Author keywords

adenocarcinoma; adenosquamous cell carcinoma; histological type; papillomavirus infection and cancer; squamous cell carcinoma; viral diversity; virus host interactions

Indexed keywords

ADULT; AFRICA; AGE DISTRIBUTION; AGED; ARTICLE; ASIA; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EUROPE; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GEOGRAPHY; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; NONHUMAN; PHYLOGENETIC TREE; PHYLOGENY; PREVALENCE; SMALL CELL CARCINOMA; SOUTH AMERICA; UTERINE CERVIX CARCINOMA; VERY ELDERLY; ADENOCARCINOMA; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PATHOGENICITY; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

VIRAL PROTEIN;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PHYLOGENY; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS;

EID: 85014119612     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30636     Document Type: Article

References (60)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase. No. 11 [Internet]. Lyon Fr Int Agency Res Cancer 2013.
2. Burk RD, Terai M, Gravitt PE, et al. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res 2003;63:7215–20.
3. Spriggs AI, Boddington MM. Progression and regression of cervical lesions. Review of smears from women followed without initial biopsy or treatment. J Clin Pathol 1980;33:517–22.
4. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994;10:31–46.
5. Baek M-H, Park J-Y, Kim D, et al. Comparison of adenocarcinoma and adenosquamous carcinoma in patients with early-stage cervical cancer after radical surgery. Gynecol Oncol 2014;135:462–7.
6. Yan M, Zhang YN, He JH, et al. Prognosis analysis of 83 cases of cervical adenosquamous carcinoma. Ai Zheng 2008;27:956–61.
7. Lai CH, Hsueh S, Hong JH, et al. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery? Int J Gynecol Cancer 1999;9:28–36.
8. Davy MLJ, Dodd TJ, Luke CG, et al. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003;101:38–45.
9. Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95:S43–S103.
10. Alfsen GC, Reed W, Abeler VM. Reproducibility of classification in non-squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2003;90:282–9.
11. Arbyn M, Verdoodt F, Snijders PJF, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;15:172–83.
12. Arbyn M, Anttila A, Jordan J, et al. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann Oncol 2010;21:448–58.
13. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32.
14. Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 2010;116:140–6.
15. Di Bonito L, Bergeron C. Cytological screening of endocervical adenocarcinoma. Ann Pathol 2012;32:e8–e14, 394–400.
16. Vizcaino AP, Moreno V, Bosch FX, et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000;86:429–35.
17. Castanon A, Landy R, Sasieni PD. Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? Int J Cancer 2016;139:1040–5.
18. Fujiwara K, Monk B, Devouassoux-Shisheboran M. Adenocarcinoma of the uterine cervix: why is it different? Curr Oncol Rep 2014;16:416.
19. Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix – worldwide. Asian Pac J Cancer Prev 2009;10:645–50.
20. Vinh-Hung V, Bourgain C, Vlastos G, et al. Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer 2007;7:164.
21. Bray F, Carstensen B, Møller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:2191–9.
22. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001;357:1490–3.
23. Castellsagué X, Diaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303–15.
24. Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States – a 24-year population-based study. Gynecol Oncol 2000;78:97–105.
25. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621–32.
26. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927–35.
27. Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796–802.
28. Altekruse SF, Lacey JV, Jr. Brinton LA, et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obs Gynecol 2003;188:657–63.
29. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–65.
30. Lacey JV, Frisch M, Brinton LA, et al. Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control 2001;12:153–61.
31. Berumen J, Ordoñez RM, Lazcano E, et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 2001;93:1325–30.
32. Pérez S, Cid A, Iñarrea A, Pato M, et al. Prevalence of HPV 16 and HPV 18 lineages in Galicia, Spain. PLoS One 2014;9:e104678.
33. Quint KD, de Koning MNC, van Doorn LJ, et al. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol 2010;117:297–301.
34. Tornesello ML, Losito S, Benincasa G, et al. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 2011;121:32–42.
35. Mirabello L, Yeager M, Cullen M, et al. HPV16 sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 women. J Natl Cancer Inst 2016;108.
36. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048–56.
37. Guimerà N, Lloveras B, Lindeman J, et al. The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol 2013;37:1299–310.
38. Nicolás-Párraga S, Gandini C, Pimenoff VN, et al. HPV16 variants distribution in invasive cancers of the cervix, vulva, vagina, penis, and anus. Cancer Med 2016;5:2909–19.
39. Stark M, Berger SA, Stamatakis A, et al. MLTreeMap – accurate maximum likelihood placement of environmental DNA sequences into taxonomic and functional reference phylogenies. BMC Genomics 2010;11:461.
40. Berger SA, Stamatakis A. Aligning short reads to reference alignments and trees. Bioinformatics 2011;27:2068–75.
41. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 2006;22:2688–90.
42. Chopjitt P, Ekalaksananan T, Pientong C, et al. Prevalence of human papillomavirus type 16 and its variants in abnormal squamous cervical cells in Northeast Thailand. Int J Infect Dis 2009;13:212–9.
43. Cornet I, Gheit T, Iannacone M. HPV16 genetic variation and the development of cervical cancer worldwide. Br J Cancer 2013;108:240–4.
44. Cornet I, Gheit T, Franceschi S. Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. J Virol 2012;86:6855–61.
45. Hu X, Pang T, Guo Z, et al. HPV16 E6 gene variations in invasive cervical squamous cell carcinoma and cancer in situ from Russian patients. Br J Cancer 2001;84:791–5.
46. Lizano M, De la Cruz-Hernández E, Carrillo-García A, et al. Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. Gynecol Oncol 2006;102:230–5.
47. Qmichou Z, Khyatti M, Berraho M, et al. Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women. BMC Infect Dis 2013;13:378.
48. Sanchez GI, Kleter B, Gheit T, et al. Clinical evaluation of polymerase chain reaction reverse hybridization assay for detection and identification of human papillomavirus type 16 variants. J Clin Virol 2011;51:165–9.
49. Pimenoff VN, Mendes de Oliveira C, Bravo IG. Transmission between archaic and modern human ancestors during the evolution of the oncogenic human papillomavirus 16. Mol Biol Evol 2016;34:4–19.
50. Chan WK, Klock G, Bernard HU. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 1989;63:3261–9.
51. Kammer C, Warthorst U, Torrez-Martinez N, et al. Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P97 promoter activity. J Gen Virol 2000;81:1975–81.
52. Lace MJ, Isacson C, Anson JR, et al. Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture. J Virol 2009;83:7457–66.
53. Sichero L, Franco EL, Villa LL. Different P105 promoter activities among natural variants of human papillomavirus type 18. J Infect Dis 2005;191:739–42.
54. Herfs M, Yamamoto Y, Laury A, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012;109:10516–21.
55. dos Reis R, Frumovitz M, Milam MR, et al. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol 2007;107:458–63.
56. Eifel PJ, Burke TW, Morris M, et al. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995;59:38–44.
57. Hopkins MP, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991;77:912–7.
58. Paloma Vizcaino A, Moreno V, Xavier Bosch F, et al. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536–45.
59. Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009;125:525–9.
60. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005;353:2101–4.